Celator Pharmaceuticals, Inc.

The Liposome Company, Inc.

Inex Pharmaceuticals Corporation

University of British Columbia

Oregon Health & Science University

Princeton University

University of Texas System

Talon Therapeutics, Inc.

Hope, Michael J.

Mayer, Lawrence D.

Madden, Thomas D.

Bally, Marcel B.

Cullis, Pieter R.

Lawrence D Mayer

Marcel B Bally

Paul Tardi

Pieter Rutter Cullis

Andrew S Janoff

Troy Harasym

Richard S Ginsberg

Murray Webb

George N Mitilenes

Michael J Hope

David K Watkins

Murray S Webb

Sharon Johnstone

Clifford Shew

Yi Zeng

Andrew Janoff

Thomas D Madden

James P Kutney

James Jackson Miller

Paul G Tardi

Jeffrey Tyner

Winnie Lui

Bruce Schmidt

Christine Swenson

Leon Wan

Max Gordon

Jo Ann Jedrusiak

Robert K Prud'homme

Robert P Lenk

Lois E Bolcsak

Patricia M Logan

Christine Allen

Andreas H Sarris

James H Goldie

Fernando Cabanillas

Nancy L Boman

Walid S Saad

John Redman

Ludger M Ickenstein

Steven M Ansell

Arthur Louie

Christine J Allen

Clive T Burge

Robert P Link

Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.

Assays and methods for selecting a treatment regimen for a subject with leukemia

Nanoparticle compositions described herein comprise combinations of prodrugs of therapeutic agents that achieve enhanced therapeutic effects as compared to those observed when combinations of free forms of these therapeutic agents are administered.

Nanoparticle delivery systems

Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.

Particulate constructs for release of active agents

Lyophilized liposomal formulations with two or more encapsulated drugs are disclosed. These formulations display superior drug retention profiles and also maintain size distribution following lyophilization and reconstitution.

Method of lyophilizing liposomes

Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.

Compositions for delivery of drug combinations

Liposomes that contain at least 10 mol % of a negatively charged lipid coupled to a non-zwitterionic moiety are stable in the blood. Liposomes containing at least 1 mol % of such lipids may be frozen safely.

Lipid carrier compositions with enhanced blood stability

Nanoparticulate formulations for delivery of taxane conjugate prodrug formed from a taxane coupled to a hydrophobic moiety through a glycolate linker are described.

Taxane delivery system

Compositions which comprise an anthracycline agent, and a cytidine analog are encapsulated in liposomal carriers. The preferred anthracycline agent is selected from the group of daunorubicin, doxorubicin, and idarubicin, while the preferred cytidine analog is selected from the group of cytarabine, gemcitabine, or 5-azacytidine. The combination of the anthracycline agent and cytidine analog encapsulated in said liposomal carriers are useful in achieving a drug retention and a sustained drug release for each therapeutic agent.

Liposomal formulations of anthracycline agents and cytidine analogs

Provided herein are methods for treating cancer by administering a pharmaceutical composition comprising a fixed, non-antagonistic molar ratio of cytarabine and an anthracycline. Such methods are particularly useful in the treatment of patients with advanced hematologic cancers or proliferative disorders.

Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders

Growing community of inventors

Vancouver, Canada

Lawrence D Mayer